Clinical Trial Update: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD [Phase 3]

View source ↗

Summary

Phase 3 study evaluating TNX-102 SL for PTSD was terminated; results have been posted as of 2025-02-06.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• TNX-102 SL (cyclobenzaprine hydrochloride)

Snippet

Sponsor: Tonix Pharmaceuticals, Inc. | Conditions: PTSD | Phase 3 | Status: TERMINATED | Results posted: 2025-02-06